- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00557856
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
September 27, 2015 updated by: Pfizer
A Phase 1 Pharmacokinetic And Pharmacodynamic Study Of Pf-03446962 In Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and effectiveness of PF-03446962 when given as a single agent.
Tumors require new blood vessels to support their ability to grow and to spread (metastasize).
New treatments aimed at preventing these blood vessels have the ability to improve the clinical management of cancer.
Study Overview
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milano, Italy, 20133
- S.C Diagnostica Radiologica 2
-
Milano, Italy, 20133
- S.C. Chirurgia Generale Indirizzo Oncologico 1 (epato-gastro-pancreatica)
-
Milano, Italy, 20133
- S.C. Medicina Oncologica I, Fondazione IRCCS Istituto Nazionale Tumori
-
Milano, Italy, 20141
- Dipartimento di Medicina
-
Rozzano (MI), Italy, 20089
- UO di Oncologia ed Ematologia, Istituto Clinico Humanitas-Humanitas Cancer Center
-
-
-
-
-
Seoul, Korea, Republic of, 110-744
- Seoul National University Hospital / Department of Internal Medicine
-
-
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina, Hollings Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
Nashville, Tennessee, United States, 37212-3505
- Vanderbilt-Ingram Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Advanced measurable or non-measurable solid tumors
- Adequate bone marrow function
- Adequate liver function
- Adequate renal function
- Be able and willing to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures
Exclusion Criteria:
- Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of first dose of study medication
- Active bleeding disorder, including gastrointestinal bleeding, as evidenced by hematemesis, hemoptysis or melena in the past 6 months
- Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident including transient ischemic attack, or pulmonary embolus; or any other active thromboembolic event
- QTc prolongation defined as QTc >450 msec
- Patients with known brain metastasis
- Patients with peritoneal carcinosis at risk of bleeding
- Major surgical procedure within 4 weeks of treatment
- Pregnancy or breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD): Part 1
Time Frame: Baseline up to 42 days after the start of each increased treatment dose
|
MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced DLT and at least 2 out of 3/6 participants in the next higher dose.
DLT was defined as any of the following events occurring during the first 42 days of study drug: any grade greater than or equal to 3 hematologic and non-hematologic toxicity, all non-disease-related adverse events (AEs).
|
Baseline up to 42 days after the start of each increased treatment dose
|
Recommended Phase 2 Dose (RP2D): Part 1
Time Frame: Baseline up to 42 days after the start of each increased treatment dose
|
RP2D was defined as the lower dose level to MTD based on the safety profile.
|
Baseline up to 42 days after the start of each increased treatment dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2
Time Frame: Cycle 1 of Day 1 up to 28 days after the last dose of treatment
|
An all causality AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.
Treatment-related AEs was any untoward medical occurrence in participant that was attributed to study drug.
Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
|
Cycle 1 of Day 1 up to 28 days after the last dose of treatment
|
Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2
Time Frame: Cycle 1 of Day 1 up to 28 days after the last dose of treatment
|
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
AE was assessed according to severity; Grade 0 (no change from normal); grade 1 (mild AE which did not cause any significant problem, no dose adjustment required); grade 2 (moderate AE which caused problem that did not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event); grade 3 (severe AE which caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event); grade 4 (life threatening AE) and grade 5 (death).
Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
|
Cycle 1 of Day 1 up to 28 days after the last dose of treatment
|
Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2
Time Frame: Cycle 1 of Day 1 up to 28 days after the last dose of treatment
|
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Seriousness of an AE was assessed as serious adverse event (SAE) and non-serious adverse event (non-SAE).
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Non-SAE included all AE minus SAE.
Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
|
Cycle 1 of Day 1 up to 28 days after the last dose of treatment
|
Time to Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2
Time Frame: Cycle 1 of Day 1 up to 28 days after the last dose of treatment
|
Total time from onset of adverse event till the event is resolved.
Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
|
Cycle 1 of Day 1 up to 28 days after the last dose of treatment
|
Number of Participants With Laboratory Abnormalities: Part 1 and Part 2
Time Frame: Cycle 1 of Day 1 up to 28 days after the last dose of treatment
|
Laboratory tests included hematology (hemoglobin, lymphocytes absolute [abs], neutrophils abs, platelets, white blood cells) and chemistry (alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hyponatremia, hypophosphatemia, lipase).
Assays were based on National Cancer Institute [NCI] Common Terminology Criteria for AE (CTCAE) grading scale for AEs (grade 1 [mild AE: did not cause any significant problem, no dose adjustment required]; grade 2 [moderate AE: caused problem that did not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event]; grade 3 [severe AE: caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event] and grade 4 [life threatening AE]).
Overall data of the 4 grades is reported.
|
Cycle 1 of Day 1 up to 28 days after the last dose of treatment
|
Percentage of Participants With Objective Response: Part 1 and Part 2
Time Frame: Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490
|
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).
Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.
CR defined as disappearance of all target lesions and non-target lesions.
PR defined as >=30 % decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non-target lesions.
|
Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490
|
Percentage of Participants With Disease Control: Part 2
Time Frame: Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490
|
Participants who achieved either a confirmed complete Response or confirmed partial response or a Stable disease lasting at least 12 weeks from the first dose was defined as achieving disease control.
Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.
CR: disappearance of all target lesions and non-target lesions.
PR: >=30 % decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD and stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as a reference the smallest sum of the LD according to RECIST associated to non-progressive disease response for non-target lesions.
Percentage of participants achieving disease control was calculated out of the participants participating in the exploratory phase.
|
Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490
|
Time To Progression (TTP): Part 2
Time Frame: Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490
|
Time in months from start of treatment to first documentation of objective tumor progression.
TTP was calculated as (first event date or last known progression-free date minus the date of treatment plus 1) divided by 30.44.
Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST).
PD: >=20% increase in the sum of the LD of the target lesions taking as a reference the smallest sum of the LD or the appearance of one or more new lesions and as unequivocal progression of existing non-target lesions, or the appearance of >=1 new lesions.
TTP was calculated out of the participants participating in the exploratory phase.
|
Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490
|
Volume of Distribution: Part 1 and Part 2
Time Frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
As per planned analysis, volume of distribution was summarized if at least 3 participants had reportable value.
|
0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2
Time Frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
|
Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2
Time Frame: 0 hr (pre dose), 1 hr post-dose C1D1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to C12
|
0 hr (pre dose), 1 hr post-dose C1D1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to C12
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2
Time Frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
|
Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2
Time Frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
AUC (0-28) = Area under the plasma concentration versus time curve from time zero (pre-dose) to Day 28 (0-28).
|
0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2
Time Frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
|
0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
Systemic Clearance(CL): Part 1 and Part 2
Time Frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
CL is a quantitative measure of the rate at which a drug substance is removed from the body.
As per planned analysis, CL was summarized if at least 3 participants had reportable value.
|
0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
Plasma Decay Half-Life (t1/2): Part 1 and Part 2
Time Frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
As per planned analysis, t1/2 was summarized if at least 3 participants had reportable value.
|
0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
|
Human Anti - Human Antibody (HAHA) Concentration: Part 1 and Part 2
Time Frame: Baseline up to 3 months after last dose
|
HAHA concentration was analyzed in blood samples for the evaluation of immunogenicity of PF-03446962.
HAHA concentration was reported for samples above lower limit of quantification (>=4.32).
|
Baseline up to 3 months after last dose
|
Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2
Time Frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Plasma concentrations of soluble proteins (Ang-2, BMP-9, C-C motif) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity.
|
Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2
Time Frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Plasma concentrations of soluble proteins (CD106, CD54 and Endoglin) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity.
|
Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2
Time Frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Plasma concentrations of soluble proteins (PLGF, TGFB1, VEGF-A) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity.
|
Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2
Time Frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Plasma concentrations of soluble proteins (VEGF-C, VEGF-d, VEGFR1) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity.
|
Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2
Time Frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Plasma concentrations of soluble proteins (VEGFR2, VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity.
|
Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Circulating Endothelial Cells (CEC)and Circulating Endothelial Progenitors (CEP): Part 1 and Part 2
Time Frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction.
Blood samples for the assessment of CECs and circulating CEPs were collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.
Circulating Cells were classified as CEPs if cluster differentiation 133 positive cells (CD133+) were detected.
|
Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Simonelli M, Zucali P, Santoro A, Thomas MB, de Braud FG, Borghaei H, Berlin J, Denlinger CS, Noberasco C, Rimassa L, Kim TY, English PA, Abbattista A, Gallo Stampino C, Carpentieri M, Williams JA. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. Ann Oncol. 2016 Sep;27(9):1782-7. doi: 10.1093/annonc/mdw240. Epub 2016 Jun 20.
- Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 May 1;22(9):2146-54. doi: 10.1158/1078-0432.CCR-15-1622. Epub 2015 Dec 11.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2007
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
March 1, 2013
Study Registration Dates
First Submitted
November 12, 2007
First Submitted That Met QC Criteria
November 12, 2007
First Posted (Estimate)
November 14, 2007
Study Record Updates
Last Update Posted (Estimate)
October 19, 2015
Last Update Submitted That Met QC Criteria
September 27, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A8471001
- 2007-001422-27 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
Clinical Trials on PF-03446962
-
NCIC Clinical Trials GroupPfizerCompletedMalignant Pleural MesotheliomaCanada
-
Duke UniversityPfizerCompletedColorectal CancerUnited States
-
PfizerTerminatedCarcinoma, HepatocellularUnited States, Japan
-
Suzhou Kintor Pharmaceutical Inc,Active, not recruitingHCC | Hepatocellular CarcinomaUnited States
-
PfizerCompleted
-
PfizerCompleted
-
PfizerCompletedSchizophreniaUnited States
-
University of FloridaCompletedGastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit TimeUnited States